# CONCORDBIO (CONCORDBIO) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/concordbio

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,494.4
- Change: +2.28%
- As of: 2026-09-18
- 1D return: +2.28%
- 5D return: +2.86%
- 1M return: -5.22%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, CONCORDBIO is trading at ₹1494.4, exhibiting a mixed technical stance across different timeframes. The daily timeframe shows the price below the Supertrend indicator (₹1580.07), suggesting potential short-term caution, despite being above key moving averages like the 20-day EMA (₹1468.4) and 50-day EMA (₹1422.89). This divergence is further highlighted by a negative SMA 20 slope over 5 periods, contrasting with a positive SMA 50 slope. The weekly timeframe presents a more constructive picture, with the price above the Supertrend (₹1158.06) and key moving averages, indicating a potential underlying bullish trend. However, the monthly timeframe reverts to a bearish Supertrend (₹1991.57) and a high ADX value (49.37), signaling strong bearish momentum on a longer-term view. Recent market activity includes a high-severity upward anomaly on September 11, 2026, characterized by a wide intraday range. The stock is currently positioned approximately 47% into its 20-day range and 71% into its 252-day range, indicating it is trading closer to the upper bounds of its recent price action over longer periods. The stock's risk profile includes an annualized volatility of 44% and a current drawdown of -36%.

- Nearest resistance is observed at ₹1507.47, approximately 0.87% above the current price.
- Nearest support is identified at ₹1490.63, approximately 0.25% below the current price.
- The daily timeframe shows the price below the Supertrend (₹1580.07), while the weekly timeframe is above its Supertrend (₹1158.06).
- A 'Morning Star' pattern is active on the daily timeframe as of September 18, 2026.
- An 'Inside Bar' pattern is active on the monthly timeframe as of September 18, 2026.

- Inside Bar
- Morning Star
- Bullish Engulfing Reversal
- Outside Bar

### News Context

Concord Biotech's U.S. Food and Drug Administration (US FDA) inspection of its Valthera Formulation Facility concluded on September 18, 2026, with a single procedural observation. This development is significant as it pertains to regulatory compliance for a key facility. Separately, on September 14, 2026, news emerged that Helios Mid Cap Fund, managed by Samir Arora, had exited three stocks, including Dixon Technologies, and added eight new ones in August. While this is a fund-level activity, it provides context on broader investor sentiment and portfolio adjustments within the mid-cap space.

- Concord Biotech's Valthera Formulation Facility completed a US FDA audit on September 18, 2026, noting one procedural observation.
- Helios Mid Cap Fund, backed by Samir Arora, exited Dixon Technologies, Aadhar Housing Finance, and Black Box in August.
- Helios Mid Cap Fund added eight new stocks, including Coforge and Lalithaa Jewellery, in August.

- Benchmarks trade near the day's high; European markets trade lower
- Concord Biotech's Valthera unit completes US FDA audit with one procedural observation
- Samir Arora-backed Helios Mid Cap Fund exits Dixon Technologies, 2 others; adds 7 stocks

### What Changed

On September 18, 2026, Concord Biotech announced the outcome of a U.S. Food and Drug Administration (USFDA) inspection at its Valthera Formulation Facility. The inspection concluded with one procedural observation. This development follows a recent increase in the company's share price, which rose from ₹1461.1 to ₹1494.4 between the previous trading day and September 18, 2026. The broader market sentiment was positive, with benchmark indices trading near day's highs, supported by easing crude oil prices and softer global bond yields, alongside an upgraded India GDP growth forecast for FY27 by Moody's.

- On September 18, 2026, Concord Biotech announced its Valthera Formulation Facility completed a US FDA inspection with one procedural observation.
- The company's share price increased to ₹1494.4 on September 18, 2026, from ₹1461.1 on the previous trading day.
- The NSE listed company, Concord Biotech, had its share price observed on September 18, 2026.

- Benchmarks trade near the day's high; European markets trade lower
- Concord Biotech's Valthera unit completes US FDA audit with one procedural observation
- Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II Valthera Formulation Facility of the Company |SUBJECT: General Updates

### Official Filings

Concord Biotech Limited has disclosed updates regarding its regulatory compliance and investor engagement. On September 18, 2026, the company announced the outcome of a U.S. Food and Drug Administration (USFDA) inspection at its Unit II Valthera Formulation Facility. Additionally, the company provided details on upcoming investor meetings. Officials are scheduled to meet with JP Morgan Healthcare Group investors and analysts in Ahmedabad on September 23, 2026, to discuss publicly available information. Earlier, on August 21, 2026, the company attended an investor conference organized by Phillip Capital PCG in Ahmedabad, also limiting discussions to publicly available information. These engagements are part of the company's ongoing communication with the investment community regarding its operations and performance.

- On September 18, 2026, Concord Biotech Limited announced the outcome of a USFDA inspection at its Unit II Valthera Formulation Facility.
- The company's officials are scheduled to meet with JP Morgan Healthcare Group investors and analysts in Ahmedabad on September 23, 2026.
- On August 21, 2026, Concord Biotech Limited officials attended an investor conference organized by Phillip Capital PCG in Ahmedabad.

- Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II Valthera Formulation Facility of the Company |SUBJECT: General Updates
- Concord Biotech Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Concord Biotech Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Concord Biotech Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### Fundamentals

Concord Biotech's recent financial performance shows a mixed trajectory. For the quarter ending September 2023 (Q2 FY24), the company reported Revenue from Operations of ₹262 crore and Profit Before Tax of ₹113 crore. However, projections for future quarters indicate a potential shift. For instance, Q3 FY2025-26 is projected to have Revenue from Operations of ₹277.77 crore and Profit Before Tax of ₹86.85 crore. Similarly, Q4 FY2025-26 is projected at ₹326.08 crore in revenue and ₹114.25 crore in Profit Before Tax, with Q1 FY2026-27 at ₹257.49 crore and ₹77.07 crore respectively. The company's operating profit margin (OPM) has shown fluctuations, standing at 45.0% in Q2 FY24, with projections for Q3 FY2025-26 at 30.0%, Q4 FY2025-26 at 33.0%, and Q1 FY2026-27 at 30.0%.

Looking at the balance sheet, borrowings have seen a significant reduction from ₹32 crore in March 2023 to ₹10 crore in March 2024, and are projected to further decrease to ₹3 crore by March 2025 and ₹1 crore by March 2026. This deleveraging is accompanied by an increase in investments, from ₹138 crore in March 2023 to ₹244 crore in March 2024, with further increases projected to ₹335 crore by March 2025 and ₹488 crore by March 2026. Cash flow from operations has remained robust, with ₹265 crore in March 2024, and projected at ₹245 crore for March 2025 and ₹264 crore for March 2026. Free cash flow was ₹180 crore in March 2024, projected at ₹134 crore for March 2025 and ₹169 crore for March 2026. The company's Return on Equity (ROE) was 13% in the last reported year, with a 3-year and 5-year average of 18%. Key monitoring areas include the trend in operating profit margins and the management of working capital, which has seen its days increase from 166 days in March 2024 to a projected 193 days in March 2025 and 231 days in March 2026.

- For the quarter ending September 2023 (Q2 FY24), Revenue from Operations was ₹262 crore and Profit Before Tax was ₹113 crore.
- Projected Revenue from Operations for Q3 FY2025-26, Q4 FY2025-26, and Q1 FY2026-27 are ₹277.77 crore, ₹326.08 crore, and ₹257.49 crore, respectively.
- Projected Profit Before Tax for Q3 FY2025-26, Q4 FY2025-26, and Q1 FY2026-27 are ₹86.85 crore, ₹114.25 crore, and ₹77.07 crore, respectively.
- Borrowings have decreased from ₹32 crore in March 2023 to a projected ₹3 crore by March 2025.
- Working Capital Days are projected to increase from 166 days in March 2024 to 231 days by March 2026.

### Bull Case

Concord Biotech's operational performance shows signs of improvement, particularly in its cash flow generation. The company's Free Cash Flow is projected to increase from ₹134.0 crore in March 2025 to ₹169.0 crore in March 2026. This is supported by an anticipated rise in Cash from Operating Activity, moving from ₹245.0 crore to ₹264.0 crore over the same period. While the company's 5-year compounded profit growth stands at 1%, the recent TTM (Trailing Twelve Months) figure shows a -20% growth, indicating a recent downturn. However, the 5-year compounded sales growth is a more robust 11%, though TTM sales growth is -6%. On the balance sheet, reserves have grown from ₹673 crore in March 2019 to ₹761 crore in March 2020, while equity capital remained steady at ₹10 crore. Fixed assets have also seen an increase from ₹230 crore to ₹240 crore over the same period. A recent development is the successful completion of a US FDA audit at the Valthera Formulation Facility with only one procedural observation, which is a positive operational update.

- Projected Free Cash Flow is expected to rise from ₹134.0 crore (Mar 2025) to ₹169.0 crore (Mar 2026).
- Cash from Operating Activity is forecasted to increase from ₹245.0 crore (Mar 2025) to ₹264.0 crore (Mar 2026).
- Reserves increased from ₹673 crore (Mar 2019) to ₹761 crore (Mar 2020).
- Concord Biotech's Valthera Formulation Facility completed a US FDA audit with one procedural observation.

- Benchmarks trade near the day's high; European markets trade lower
- Concord Biotech's Valthera unit completes US FDA audit with one procedural observation
- Samir Arora-backed Helios Mid Cap Fund exits Dixon Technologies, 2 others; adds 7 stocks

### Bear Case

Concord Biotech's financial performance shows signs of strain, with a notable decline in profitability over the last twelve months (TTM). Sales have also contracted in the TTM period, contrasting with a longer-term growth trend. The company's balance sheet indicates a significant increase in borrowings and capital work-in-progress (CWIP) between March 2019 and March 2020, while investments decreased. From a technical standpoint, the daily and monthly trends are indicated as bearish, with the current price trading below key moving averages and the Supertrend indicator suggesting a bearish direction on a daily basis. The stock has experienced substantial drawdowns, with a current drawdown of -36% and a maximum drawdown of -57%.

- Compounded profit growth was -20% for the TTM period, compared to 1% over 5 years.
- Compounded sales growth was -6% for the TTM period, compared to 11% over 5 years.
- Borrowings increased from ₹9 crore in March 2019 to ₹52 crore in March 2020.
- Capital Work-In-Progress (CWIP) increased from ₹19 crore in March 2019 to ₹141 crore in March 2020.
- The current drawdown is -36% and the maximum drawdown is -57%.

- Benchmarks trade near the day's high; European markets trade lower
- Concord Biotech's Valthera unit completes US FDA audit with one procedural observation
- Samir Arora-backed Helios Mid Cap Fund exits Dixon Technologies, 2 others; adds 7 stocks

### FAQs

**What was the outcome of the US FDA inspection at Concord Biotech's Valthera Formulation Facility?**

The U.S. Food and Drug Administration (US FDA) concluded its inspection of Concord Biotech's Valthera Formulation Facility with one minor procedural observation. This was announced on September 18, 2026.

**How has Concord Biotech's financial performance changed over the last five years compared to the Trailing Twelve Months (TTM)?**

Over the last five years, Concord Biotech has shown a compounded sales growth of 11% and a compounded profit growth of 1%. However, for the Trailing Twelve Months (TTM), compounded sales growth was -6% and compounded profit growth was -20%.

**What are the key financial metrics for Concord Biotech as of March 2020 compared to March 2019?**

As of March 2020, Concord Biotech reported Total Assets of ₹941 crore and Total Liabilities of ₹941 crore. This compares to ₹763 crore in Total Assets and ₹763 crore in Total Liabilities as of March 2019. Reserves stood at ₹761 crore in March 2020, up from ₹673 crore in March 2019. Borrowings increased significantly to ₹52 crore in March 2020 from ₹9 crore in March 2019, and CWIP rose to ₹141 crore from ₹19 crore over the same period.

**What are the projected cash flow figures for Concord Biotech for the fiscal years ending March 2025 and March 2026?**

For the fiscal year ending March 2025, Concord Biotech is projected to have Cash from Operating Activity of ₹245.0 crore and Free Cash Flow of ₹134.0 crore. For the fiscal year ending March 2026, these figures are projected to be ₹264.0 crore for Cash from Operating Activity and ₹169.0 crore for Free Cash Flow. Net Cash Flow is projected at -₹14.0 crore for March 2025 and ₹7.0 crore for March 2026. Cash from Financing Activity is expected to be -₹99.0 crore and -₹115.0 crore for March 2025 and March 2026, respectively.

**What is the current technical trend for Concord Biotech based on daily and weekly indicators?**

On a daily timeframe as of September 18, 2026, the Supertrend indicator suggests a bearish direction, with the closing price of ₹1494.4 being above the 20-day Exponential Moving Average (EMA) of ₹1468.4. On a weekly timeframe, the Supertrend indicator shows a bullish direction, with the closing price of ₹1494.4 above the 20-week EMA of ₹1364.86.

- Benchmarks trade near the day's high; European markets trade lower
- Concord Biotech's Valthera unit completes US FDA audit with one procedural observation
- Samir Arora-backed Helios Mid Cap Fund exits Dixon Technologies, 2 others; adds 7 stocks
- Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II Valthera Formulation Facility of the Company |SUBJECT: General Updates
- Concord Biotech Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Concord Biotech Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Concord Biotech Limited has informed the Exchange about Transcript |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,459.03
- Risk regime: Higher Price Risk

### Support levels
- 1473.71015625
- 1420.4875000000002
- 1373.928125

### Resistance levels
- 1607
- 1647.8
- 1674.4

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +2.28% |
| return_10 | +3.23% |
| return_1m | -4.55% |
| return_1y | -9.85% |
| return_20 | -5.22% |
| return_3m | +10.90% |
| return_5 | +2.86% |
| return_6m | +30.76% |
| return_since_start | -30.45% |
| return_ytd | +11.83% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -56.74% |
| annualized_volatility | +44.12% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Sequential Decline in Revenue and Profit Masks Year-over-Year Growth

In the quarter ended 30 June 2026, Concord Biotech Limited’s revenue and profit fell from the record levels of the March 2026 quarter. Compared to the same quarter a year ago, however, both revenue and profit grew substantially. Profit margins expanded modestly, and other income added ₹12.83 crore to earnings.

## Revenue and Profit Trends: Year-over-Year and Sequential

Revenue from operations was ₹257.49 crore in the June 2026 quarter, down 21% from ₹326.08 crore in the March 2026 quarter, but up 26% from ₹203.99 crore in the June 2025 quarter. Profit before tax followed a similar pattern: ₹77.07 crore, decreasing 33% from ₹114.25 crore in the prior quarter, but increasing 35% from ₹57.24 crore a year ago. Profit after tax was ₹57.70 crore, down 35% from ₹88.47 crore in the previous quarter, but up 31% from ₹44.06 crore in the same quarter last year.

The current quarter’s revenue is higher than each of the first three quarters of the previous fiscal year (₹203.99 crore, ₹247.06 crore, ₹277.77 crore) but lower than the fourth quarter. This aligns with the prior year’s quarterly progression, where revenue was lowest in the first quarter and highest in the fourth.

## Cost Structure and Profitability

Material-related costs—comprising cost of materials consumed (₹69.85 crore), purchases of stock in trade (₹11.29 crore), and changes in inventories (a credit of ₹26.85 crore)—totaled a net of ₹54.29 crore, or 21% of revenue. Employee benefit expense was ₹43.64 crore (17% of revenue), and depreciation and amortization was ₹18.10 crore (7% of revenue). Finance costs remained negligible at ₹3.64 lakh.

Other income of ₹12.83 crore, equivalent to about 5% of revenue, added to earnings.

Profit before tax margin was 29.9% (₹77.07 crore / ₹257.49 crore), and profit after tax margin was 22.4% (₹57.70 crore / ₹257.49 crore). In the year-ago quarter, the corresponding margins were 28.1% and 21.6%, respectively, indicating a modest improvement in profitability.

## Other Income and Associate Contribution

Other income for the quarter was ₹12.83 crore. The income statement also includes a share of profit from associates and joint ventures of ₹1.28 crore. This line item appears for the first time in the reported periods and is presented after tax expense. Its inclusion means that net profit (₹57.70 crore) is ₹1.28 crore higher than profit before tax (₹77.07 crore) minus tax expense (₹20.65 crore).

## Key Takeaway

Concord Biotech’s June 2026 quarter saw revenue and profit decline from the record levels of the March 2026 quarter, but both remained significantly higher than the June 2025 quarter. Profit margins improved modestly year-on-year, and other income contributed ₹12.83 crore. A new line item for share of profit from associates added ₹1.28 crore to net profit.

### Ratios

## Official filings

- 2026-09-18 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_18092026102702_Intimation_to_Stock_Exchanges_-_USFDA.pdf)
- 2026-09-17 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_17092026111327_Intimation_to_Stock_Exchanges.pdf)
- 2026-08-21 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_21082026101908_Intimation_to_Stock_Exchanges.pdf)
- 2026-08-07 — Generic Announcement: Concord Biotech Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_07082026150507_EarningsCallTranscriptQ127.pdf)
- 2026-08-03 — Generic Announcement: Concord Biotech Limited successfully conducted its earnings call for the first quarter ended June 30, 2026, on August 3, 2026. The audio recording of this call, which discussed the unaudited financial results, is now available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_03082026181124_Q1FY27EarningCallOutcome.pdf)
- 2026-08-01 — Generic Announcement: Concord Biotech Limited has released its investor presentation for the first quarter ended June 30, 2026, detailing unaudited standalone and consolidated financial results. The company reported a 26% year-on-year revenue growth in Q1FY27, with export revenue increasing by 46%. Key highlights include USFDA approvals for Mycophenolate Mofetil & Tofacitinib Tablets, successful regulatory inspections by ANVISA, PPB Kenya, and NDA Uganda, and receiving an EcoVadis Silver Medal for sustainability. Consolidated revenue was Rs. 257 Crs, EBITDA Rs. 82 Crs, and PAT Rs. 58 Crs for Q1FY27. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_01082026185647_InvestorPresentationQ127.pdf)
- 2026-08-01 — Generic Announcement: Concord Biotech Limited published its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, on August 1, 2026. These results were reviewed by the Audit Committee and approved by the Board of Directors on July 31, 2026. The financial results have also been uploaded to the company's website in compliance with listing regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_01082026135108_NewspaperCutouts01082026.pdf)
- 2026-08-01 — Generic Announcement: Concord Biotech Limited held its 41st Annual General Meeting on July 31, 2026, where all six resolutions, including the adoption of financial statements, declaration of dividend, appointment of directors, and approval of loan limits to subsidiaries, were passed with the requisite majority. The voting results and the scrutinizer's report were submitted on August 1, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_01082026175352_Voting_results_41st_AGM.pdf)
- 2026-07-31 — Generic Announcement: Concord Biotech Limited's Board of Directors, on July 31, 2026, approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The company also reported an incremental liability of Rs. 327.54 lakhs due to the statutory impact of new labor codes, recognized as an exceptional item. The financial results were reviewed by the Audit Committee and BSR & Co. LLP, the statutory auditors. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_31072026181713_Outcome_BM31072026.pdf)
- 2026-07-31 — Generic Announcement: Concord Biotech Limited held its 41st Annual General Meeting on July 31, 2026, via Video Conferencing. The meeting, attended by 38 members, included addresses by the Chairman and Managing Director on the company's financial performance for the year ended March 31, 2026, and future prospects. Voting results on resolutions are expected within two working days and will be submitted to regulatory bodies and posted on the company website. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_31072026195531_AGMIntimation31072026.pdf)
- 2026-07-28 — Generic Announcement: Concord Biotech Limited announced an earnings call scheduled for August 3, 2026, at 3:30 PM IST to discuss the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The call will include the Chairman & Managing Director, Joint Managing Director and CEO, and Chief Financial Officer. This disclosure is made pursuant to SEBI regulations. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_28072026195512_Concord_Intimation_of_earning_call.pdf)
- 2026-07-28 — Official Filing: Concord Biotech Limited will hold a board meeting on July 31, 2026, to consider its unaudited financial results for the quarter ended June 2026. The trading window for the company's securities will be closed from July 1, 2026, to August 2, 2026.
- 2026-07-08 — Generic Announcement: Concord Biotech Limited is publishing newspaper advertisements regarding its 41st Annual General Meeting (AGM), including details on director candidacies, the record date, and e-voting availability. The AGM is scheduled to be held on August 4, 2026, via video conference, with e-voting commencing on August 1, 2026, and concluding on August 3, 2026. The record date for dividend identification and the 41st AGM is July 24, 2026, with remote e-voting available from July 28 to July 30, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_08072026135736_Intimation_Post_dispatch_newspaper.pdf)
- 2026-07-07 — Official Filing: Concord Biotech Limited will hold its 41st Annual General Meeting on Friday, July 31, 2026, at 12:00 PM in Ahmedabad, conducted via Video Conference or Other Audio-Visual Means. The agenda includes the adoption of financial statements, declaration of dividend, appointment of Mr. Ankur Vaid as an Executive Director and Mrs. Ekta Gupta as an Independent Director, approval of enhanced limits for loans and guarantees to subsidiaries, and ratification of cost auditors' remuneration.
- 2026-07-07 — Generic Announcement: Concord Biotech Limited will hold its 41st Annual General Meeting on July 31, 2026, via video conference. Key agenda items include adopting the FY2025-26 financial statements, declaring a dividend of ₹7.55 per equity share, re-appointing Mr. Ankur Vaid as a director, and appointing Mrs. Ekta Gupta as an independent director. The company also seeks approval to enhance its limit for advancing loans, guarantees, and securities to subsidiary, associate, and joint venture companies up to ₹500 Crores. Additionally, the remuneration of Cost Auditors, M/s. Dalwadi & Associates, for FY2026-27, set at ₹3,70,000 plus applicable GST and expenses, will be ratified. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_07072026155145_Intimation_Notice_of_AGM.pdf)
- 2026-07-07 — Generic Announcement: Concord Biotech Limited will hold its 41st Annual General Meeting on July 31, 2026, to approve the final dividend for the financial year ended March 31, 2026. The company has set July 24, 2026, as the record date for dividend entitlement. The Register of Members and Share Transfer Books will be closed from July 25, 2026, to July 31, 2026. Dividend payments, if approved, will be distributed by August 30, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_07072026173416_Record_date_and_Book_closure.pdf)
- 2026-07-06 — Generic Announcement: Concord Biotech Limited has submitted a certificate for the quarter ended June 30, 2026, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. MUFG Intime India Private Limited, the Registrar and Share Transfer Agent, confirmed that securities received for dematerialization were processed and listed on stock exchanges within the prescribed timelines. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_06072026133226_Disclosures_Reg_74_5.pdf)
- 2026-07-06 — Generic Announcement: Concord Biotech Limited has published newspaper advertisements regarding its 41st Annual General Meeting, including details on director candidatures, record dates, and e-voting facilities. Separately, BOGATI CAPRE LLP proposes to shift its registered office from Karnataka to Kerala, with objections to be submitted within 21 days. Sushma Pramod Construction Private Limited is seeking Central Government confirmation to change its registered office from Karnataka to Andhra Pradesh, with objections to be filed within fourteen days of notice publication. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_06072026144654_Intimation_Pre_dispatch_newspaper.pdf)
- 2026-06-27 — Generic Announcement: Concord Biotech Limited will close its trading window for equity shares from July 01, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ended June 30, 2026. All designated persons and their immediate relatives are prohibited from trading in the company's securities during this period. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_27062026110818_Concord_Intimation_Closure_of_Trading_window.pdf)
- 2026-06-25 — Generic Announcement: Concord Biotech Limited announced the successful completion of inspections by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. The inspections occurred from June 18, 2026, to June 24, 2026. This successful outcome is considered a significant milestone for the company's global growth and regulatory standing. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_25062026100809_Intimation_PPB_NDA.pdf)
- 2026-06-20 — Generic Announcement: Concord Biotech Limited has entered into an agreement to invest Rs. 6.3 Crores for a 27.38% equity stake in FSGE Renewable Power Private Limited. This investment is for the installation of a 6.3 MW AC Wind and 6.3 MWp DC Solar hybrid power project in Gujarat for Concord Biotech's Limbasi Facility. FSGE, a Special Purpose Vehicle incorporated on August 19, 2023, is yet to commence commercial operations. The acquisition is considered a related party transaction and will be completed within 60 days from the agreement date. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_20062026183731_Intimation_Acquisition_-_FSGE.pdf)
- 2026-06-19 — Generic Announcement: Concord Biotech Limited officials will participate in a Non-Deal Roadshow (NDR) to meet investors on June 24th and 25th, 2026, in Mumbai. The meetings, organized by Kotak Institutional Equities, will involve 1x1 or group discussions based solely on publicly available information, with no unpublished price sensitive information intended for disclosure. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_19062026151726_Intimation_to_Stock_Exchanges.pdf)
- 2026-06-13 — Generic Announcement: Concord Biotech Limited will hold virtual investor and analyst meetings on June 17, 2026, starting at 10:30 am. Discussions will be limited to publicly available information, and no unpublished price sensitive information will be disclosed. This intimation is in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_13062026111530_Intimation_to_Stock_Exchanges.pdf)
- 2026-06-12 — Generic Announcement: Concord Biotech Limited announced the successful completion of an ANVISA inspection by the Brazilian Health Regulatory Agency at its Limbasi API manufacturing facility. The inspection occurred from June 8 to June 12, 2026, and its successful conclusion is considered a milestone for the company's global growth and international expansion strategy. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_12062026133511_Intimation_ANVISA.pdf)
- 2026-06-10 — Generic Announcement: Concord Biotech Limited has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for its Tofacitinib Tablets, 5 mg and 10 mg. This approval is for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The U.S. market for Tofacitinib Tablets is estimated at approximately US$ 500 million, and this approval aligns with Concord Biotech's growth strategy and strengthens its U.S. market position. — [Official attachment](https://nsearchives.nseindia.com/corporate/CONCORD_10062026101245_Intimation_ANDA.pdf)

## News and market events

- 2026-09-18 — BUSINESS: **Nifty settles above 23,300 as Moody's GDP upgrade, easing oil support sentiment** — The key equity benchmarks ended mixed on Friday, as easing crude oil prices and softer global bond yields supported investor sentiment. Market sentiment was also aided by Moody's upward revision of India's FY27 GDP growth forecast to 7% from 6%, citing stronger-than-expected domestic activity and the resilience of the economy amid the ongoing conflict in West Asia. However, Moody's flagged elevated energy prices and El Ni-related food price pressures as risks to inflation, consumption and growth. — [Source](https://www.business-standard.com/markets/capital-market-news/nifty-settles-above-23-300-as-moody-s-gdp-upgrade-easing-oil-support-sentiment-126091800939_1.html)
- 2026-09-18 — BUSINESS: **Indices end sideways; metal shares shine for 3rd day** — In the primary market, the NSE IPO was fully subscribed, while investors continued to track subscription trends in other ongoing issues and monitor the listing performance of recently listed companies. — [Source](https://www.business-standard.com/markets/capital-market-news/indices-end-sideways-metal-shares-shine-for-3rd-day-126091800788_1.html)
- 2026-09-18 — BUSINESS: **Benchmarks trade near the day's high; European markets trade lower** — The benchmark indices traded near the day's high in afternoon trade, supported by easing crude oil prices and softer global bond yields. Market sentiment also received a boost after Moodys raised its India FY27 GDP growth forecast to 7%, citing the resilience of the domestic economy despite ongoing geopolitical tensions in West Asia. The Nifty regained the 23,300 mark. — [Source](https://www.business-standard.com/markets/capital-market-news/benchmarks-trade-near-the-day-s-high-european-markets-trade-lower-126091800572_1.html)
- 2026-09-18 — BUSINESS: **Concord Biotech's Valthera unit completes US FDA audit with one procedural observation** — Concord Biotech said that the U.S. Food and Drug Administration (US FDA) had successfully concluded the inspection of the company's Valthera Formulation Facility, with one minor procedural observation. — [Source](https://www.business-standard.com/markets/capital-market-news/concord-biotech-s-valthera-unit-completes-us-fda-audit-with-one-procedural-observation-126091800453_1.html)
- 2026-09-14 — Economic Times: **Samir Arora-backed Helios Mid Cap Fund exits Dixon Technologies, 2 others; adds 7 stocks** — Helios Mid Cap Fund, backed by Samir Arora, exited Dixon Technologies, Aadhar Housing Finance and Black Box in August. The fund added eight stocks, including Coforge and Lalithaa Jewellery, while increasing exposure to 15 stocks and holding 72 stocks across 23 sectors. — [Source](https://economictimes.indiatimes.com/mf/analysis/samir-arora-backed-helios-mid-cap-fund-exits-dixon-technologies-2-others-adds-7-stocks/articleshow/134231976.cms)
- 2026-09-01 — CNBC-TV18: **Symbiotec Pharmalab shares to list today; GMP signals 19% premium over IPO price** — If grey market trends are anything to go by, the stock could make a strong debut with a premium of around 19% over its issue price. The grey market premium (GMP) currently stands at ₹185, indicating an estimated listing price of around ₹1,173 per share, compared with the IPO price of ₹988. — [Source](https://www.cnbctv18.com/market/symbiotec-pharmalab-share-price-ipo-listing-today-premium-discount-gmp-signals-issue-price-nse-bse-19980955.htm)
- 2026-08-24 — The Hindu: **Symbiotec Pharmalab IPO sees subscription at 0.70x by mid-afternoon** — The employee reservation portion led with 1.19 times subscription; Retail Individual Investors subscription at 0.82 times, NII category is at 0.86 times. QIB remained the weakest segment at 0.35 times — [Source](https://www.thehindubusinessline.com/markets/symbiotec-pharmalab-ipo-sees-subscription-at-070x-by-mid-afternoon/article71384017.ece)
- 2026-08-24 — Economic Times: **Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?** — Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity. — [Source](https://economictimes.indiatimes.com/markets/ipos/fpos/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133448856.cms)
- 2026-08-18 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Concord Biotech (₹1,513.40) – BUY** — Sensex, Nifty, Share Prices LIVE: The short-term outlook is bullish for Concord Biotech. The stock began the week on a strong note, rising 4.2 per cent on Monday — [Source](https://www.thehindubusinessline.com/markets/stock-market-live-sensex-nifty50-today-live-updates-today-18th-august-2026/article71358725.ece)
- 2026-08-17 — Economic Times: **Market Trading Guide: Hindustan Copper among 2 stock recommendations for Tuesday** — Analysts recommend Hindustan Copper and Concord Biotech after both stocks broke key resistance levels with strong price action, volume and bullish momentum. Despite energy-led cost pressures, stronger Q1FY27 earnings and pricing actions could support upgrades, though margin risks remain from higher-cost inventory. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/market-trading-guide-hindustan-copper-among-2-stock-recommendations-for-tuesday/articleshow/133300251.cms)
- 2026-08-10 — CNBC-TV18: **Top 8 Nifty 500 movers: From Hitachi Energy to Kaynes Tech, here are the biggest gainers and losers at opening** — The Nifty 500 saw active trading at market open today, with power, diagnostics and travel-tech names leading gains while electronics manufacturing and fashion retail slipped.Here's a look at the stocks that stood out as today's biggest movers on the index this morning. — [Source](https://www.cnbctv18.com/photos/market/nifty-500-top-gainers-losers-market-open-hitachi-energy-vijaya-diagnostics-kaynes-ola-electric-19965194.htm)
- 2026-08-10 — MONEYCONTROL: **Trade Spotlight: How should you trade Uno Minda, Glenmark Pharma, APL Apollo Tubes, Grasim Industries, TCS, and others on August 10?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Uno Minda,Glenmark Pharmaceuticals,APL Apollo Tubes,BLS International Services,Concord Biotech,Grasim Industries,Vedanta,Tata Consultancy Services — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-uno-minda-glenmark-pharma-apl-apollo-tubes-grasim-industries-tcs-and-others-on-august-10-13999267.html)
- 2026-08-05 — Economic Times: **Stock Radar: Concord Biotech stock showing signs of rebound after falling over 20% from highs; time to buy?** — Concord Biotech stock shows a breakout from a seven-month consolidation phase. Experts suggest buying the stock for a target above 1,500 levels. The pharma stock experienced a significant fall after reaching record highs previously. It has since formed a strong base and is trading above key moving averages. Momentum indicators support a bullish outlook for the stock in the coming weeks. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stock-radar-concord-biotech-stock-showing-signs-of-rebound-after-falling-over-20-from-highs-time-to-buy/articleshow/132856690.cms)
- 2026-07-31 — CNBC-TV18: **Q1 Results LIVE Updates:  IOC slips into loss; Maruti Suzuki profit beats estimates** — Q1 Results LIVE Updates: Four Nifty companies, ITC, Maruti Suzuki, Sun Pharma and Bajaj Finserv report results today to round off this week dominated by earnings. Broader market names like Dixon Tech, Indian Oil, Glenmark Pharma, GMDC, ABB India, SJVN, GAIL and NALCO among many others will also be reporting their results. The big result reactions of the day include the likes of Swiggy, Mazagon Dock, Thermax, Bajaj Finance's earnings call and upgrades among others. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-sun-pharma-itc-maruti-suzuki-bajaj-finserv-tata-steel-swiggy-share-price-liveblog-19958383.htm)
- 2026-07-30 — Mint: **Raja Venkatraman recommends three stocks for 30 July** — Market expert Raja Venkatraman shares his top stock picks for 30 July. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-30-july-11785342562112.html)

## Business profile

**Strategic vision:** Biopharmaceutical company developing and manufacturing APIs and formulations.

### Business segments
- **Active Pharmaceutical Ingredients (API):** The company manufactures niche and reliable APIs using fermentation and semi-synthetic methods, maintaining high-quality benchmarks. The API facility is dedicated to producing high-quality APIs.
- **Formulations:** Concord Biotech develops and manufactures niche formulations aimed at improving health outcomes for patients globally. This segment includes both global formulations and branded generic products for the Indian market.
- **Contract Development & Manufacturing Services (CDMO):** The company provides comprehensive Contract Development & Manufacturing Services, supported by technical expertise and adhering to global regulatory approvals.

### Competitive strengths
- Over two and a half decades of experience in the biopharmaceutical industry.
- Leveraging advanced fermentation and semi-synthetic technologies.
- State-of-the-art manufacturing facilities meeting stringent international quality standards.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.25%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.78%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.80%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +2.21%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — +0.12%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/concordbio
Markdown representation: https://faxioms.com/stocks/concordbio?render=md